Focused On-demand Library for Zinc finger C4H2 domain-containing protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NQZ6

UPID:

ZC4H2_HUMAN

Alternative names:

Hepatocellular carcinoma-associated antigen 127

Alternative UPACC:

Q9NQZ6; B2RDC2; B3KVZ5; B4DED0; E7EM74; G3V1L3; Q53H73; Q5JTF9; Q9H9C3; Q9H9H7; Q9ULQ4

Background:

The Zinc finger C4H2 domain-containing protein, also known as Hepatocellular carcinoma-associated antigen 127, plays a pivotal role in the differentiation of interneurons and is crucial for neuronal development and neuromuscular junction formation. Its involvement in these fundamental processes underscores its importance in the central and peripheral nervous systems.

Therapeutic significance:

Linked to severe neurodevelopmental disorders such as Wieacker-Wolf syndrome and its female-restricted variant, understanding the role of this protein could open doors to potential therapeutic strategies. These conditions, characterized by muscle weakness, contractures, and developmental delays, highlight the protein's critical role in neuromuscular development.